within Pharmacolibrary.Drugs.ATC.S;

model S01AE04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.14 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.0018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015000000000000001,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Lomefloxacin is a fluoroquinolone antibiotic used primarily to treat bacterial infections, particularly urinary tract infections and conjunctivitis (when used topically in ophthalmology, ATC code S01AE04). The drug has been withdrawn from the US and EU markets due to adverse effects, but may be available in some countries for human or veterinary use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Freeman, CD, et al., &amp; Nightingale, CH (1993). Lomefloxacin clinical pharmacokinetics. <i>Clinical pharmacokinetics</i> 25(1) 6–19. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199325010-00002&quot;>10.2165/00003088-199325010-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8394795/&quot;>https://pubmed.ncbi.nlm.nih.gov/8394795</a></p></li><li><p>Rodvold, KA, &amp; Piscitelli, SC (1993). New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 17 Suppl 1 S192–S199. DOI:<a href=&quot;https://doi.org/10.1093/clinids/17.supplement_1.s192&quot;>10.1093/clinids/17.supplement_1.s192</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8399914/&quot;>https://pubmed.ncbi.nlm.nih.gov/8399914</a></p></li><li><p>Morrison, PJ, et al., &amp; Kunka, RL (1988). Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. <i>Antimicrobial agents and chemotherapy</i> 32(10) 1503–1507. DOI:<a href=&quot;https://doi.org/10.1128/AAC.32.10.1503&quot;>10.1128/AAC.32.10.1503</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3214495/&quot;>https://pubmed.ncbi.nlm.nih.gov/3214495</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01AE04;
